Targeting of extracellular proteases required for the progression of pancreatic cancer

Bibliography

• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30
   PubMed Web of Science ®Google Scholar
• Michalski CW, Weitz J, Buchler MW. Surgery insight: surgical management of pancreatic cancer. Nat Clin Pract Oncol 2007;4:526-35
   PubMedGoogle Scholar
• Michaud DS. Epidemiology of pancreatic cancer. Minerva Chir 2004;59:99-111
   PubMedGoogle Scholar
• Hassan MM, Bondy ML, Wolff RA, et al. Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol 2007;102:2696-707
   PubMed Web of Science ®Google Scholar
• Whitcomb DC. Inflammation and Cancer V. Chronic pancreatitis and pancreatic cancer. Am J Physiol Gastrointest Liver Physiol 2004;287:G315-9
   PubMed Web of Science ®Google Scholar
• Hruban RH, Iacobuzio-Donahue C, Wilentz RE, et al. Molecular pathology of pancreatic cancer. Cancer J 2001;7:251-8
   PubMed Web of Science ®Google Scholar
• Hezel AF, Kimmelman AC, Stanger BZ, et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006;20:1218-49
   PubMed Web of Science ®Google Scholar
• Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002;2:897-909
   PubMed Web of Science ®Google Scholar
• Guerra C, Mijimolle N, Dhawahir A, et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 2003;4:111-20
   PubMed Web of Science ®Google Scholar
• Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003;4:437-50
   PubMed Web of Science ®Google Scholar
• Ijichi H, Chytil A, Gorska AE, et al. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-β signaling in cooperation with active Kras expression. Genes Dev 2006;20:3147-60
   PubMed Web of Science ®Google Scholar
• Bardeesy N, Cheng KH, Berger JH, et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev 2006;20:3130-46
   PubMed Web of Science ®Google Scholar
• Bardeesy N, Aguirre AJ, Chu GC, et al. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci USA 2006;103:5947-52
   PubMed Web of Science ®Google Scholar
• Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005;7:469-83
   PubMed Web of Science ®Google Scholar
• Lopez-Otin C, Matrisian LM. Emerging roles of proteases in tumour suppression. Nat Rev Cancer 2007;7:800-8
   PubMed Web of Science ®Google Scholar
• Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260-70
   PubMed Web of Science ®Google Scholar
• Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature 1997;385:729-33
   PubMed Web of Science ®Google Scholar
• Blobel CP. Remarkable roles of proteolysis on and beyond the cell surface. Curr Opin Cell Biol 2000;12:606-12
   PubMed Web of Science ®Google Scholar
• Seals DF, Courtneidge SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 2003;17:7-30
   PubMed Web of Science ®Google Scholar
• White JM. ADAMs: modulators of cell-cell and cell-matrix interactions. Curr Opin Cell Biol 2003;15:598-606
   PubMed Web of Science ®Google Scholar
• Black RA, White JM. ADAMs: focus on the protease domain. Curr Opin Cell Biol 1998;10:654-9
   PubMed Web of Science ®Google Scholar
• Becherer JD, Blobel CP. Biochemical properties and functions of membrane-anchored metalloprotease-disintegrin proteins (ADAMs). Curr Top Dev Biol 2003;54:101-23
   PubMedGoogle Scholar
• Ringel J, Jesnowski R, Moniaux N, et al. Aberrant expression of a disintegrin and metalloproteinase 17/tumor necrosis factor-α converting enzyme increases the malignant potential in human pancreatic ductal adenocarcinoma. Cancer Res 2006;66:9045-53
   PubMedGoogle Scholar
• Moss ML, Jin SL, Milla ME, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α. Nature 1997;385:733-6
   PubMed Web of Science ®Google Scholar
• Tisdale MJ. Biology of cachexia. J Natl Cancer Inst 1997;89:1763-73
   PubMed Web of Science ®Google Scholar
• Inoue J, Gohda J, Akiyama T, Semba K. NF-κB activation in development and progression of cancer. Cancer Sci 2007;98:268-74
   PubMed Web of Science ®Google Scholar
• Peschon JJ, Slack JL, Reddy P, et al. An essential role for ectodomain shedding in mammalian development. Science 1998;282:1281-4
   PubMed Web of Science ®Google Scholar
• Sunnarborg SW, Hinkle CL, Stevenson M, et al. Tumor necrosis factor-α converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability. J Biol Chem 2002;277:12838-45
   PubMed Web of Science ®Google Scholar
• Borrell-Pages M, Rojo F, Albanell J, et al. TACE is required for the activation of the EGFR by TGF-α in tumors. EMBO J 2003;22:1114-24
   PubMed Web of Science ®Google Scholar
• Sahin U, Weskamp G, Kelly K, et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 2004;164:769-79
   PubMed Web of Science ®Google Scholar
• Korc M, Chandrasekar B, Yamanaka Y, et al. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest 1992;90:1352-60
   PubMed Web of Science ®Google Scholar
• Friess H, Berberat P, Schilling M, et al. Pancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptors. J Mol Med 1996;74:35-42
   PubMedGoogle Scholar
• Means AL, Meszoely IM, Suzuki K, et al. Pancreatic epithelial plasticity mediated by acinar cell transdifferentiation and generation of nestin-positive intermediates. Development 2005;132:3767-76
   PubMed Web of Science ®Google Scholar
• Sandgren EP, Luetteke NC, Palmiter RD, et al. Overexpression of TGFα in transgenic mice: induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell 1990;61:1121-35
   PubMed Web of Science ®Google Scholar
• Maruta H, Burgess AW. Regulation of the Ras signalling network. Bioessays 1994;16:489-96
   PubMedGoogle Scholar
• Siveke JT, Einwachter H, Sipos B, et al. Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN. Cancer Cell 2007;12:266-79
   PubMed Web of Science ®Google Scholar
• Perez-Moreno M, Fuchs E. Catenins: keeping cells from getting their signals crossed. Dev Cell 2006;11:601-12
   PubMed Web of Science ®Google Scholar
• Noe V, Fingleton B, Jacobs K, et al. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 2001;114:111-8
   PubMed Web of Science ®Google Scholar
• Maretzky T, Reiss K, Ludwig A, et al. ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and β-catenin translocation. Proc Natl Acad Sci USA 2005;102:9182-7
   PubMed Web of Science ®Google Scholar
• Ito K, Okamoto I, Araki N, et al. Calcium influx triggers the sequential proteolysis of extracellular and cytoplasmic domains of E-cadherin, leading to loss of β-catenin from cell-cell contacts. Oncogene 1999;18:7080-90
   PubMed Web of Science ®Google Scholar
• Radisky DC, Levy DD, Littlepage LE, et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 2005;436:123-7
   PubMed Web of Science ®Google Scholar
• Lochter A, Galosy S, Muschler J, et al. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol 1997;139:1861-72
   PubMed Web of Science ®Google Scholar
• Schneikert J, Behrens J. The canonical Wnt signalling pathway and its APC partner in colon cancer development. Gut 2007;56:417-25
   PubMed Web of Science ®Google Scholar
• Segditsas S, Tomlinson I. Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene 2006;25:7531-7
   PubMed Web of Science ®Google Scholar
• Wells JM, Esni F, Boivin GP, et al. Wnt/β-catenin signaling is required for development of the exocrine pancreas. BMC Dev Biol 2007;7:4. Published online 12 January 2007, doi:10.1186/1471-213X-7-
   PubMed Web of Science ®Google Scholar
• Qiao Q, Ramadani M, Gansauge S, et al. Reduced membranous and ectopic cytoplasmic expression of β-catenin correlate with cyclin D1 overexpression and poor prognosis in pancreatic cancer. Int J Cancer 2001;95:194-7
   PubMed Web of Science ®Google Scholar
• Al-Aynati MM, Radulovich N, Riddell RH, Tsao MS. Epithelial-cadherin and β-catenin expression changes in pancreatic intraepithelial neoplasia. Clin Cancer Res 2004;10:1235-40
   PubMed Web of Science ®Google Scholar
• Gumbiner BM. Regulation of cadherin adhesive activity. J Cell Biol 2000;148:399-404
   PubMedGoogle Scholar
• Pan D, Rubin GM. Kuzbanian controls proteolytic processing of Notch and mediates lateral inhibition during Drosophila and vertebrate neurogenesis. Cell 1997;90:271-80
   PubMed Web of Science ®Google Scholar
• Brou C, Logeat F, Gupta N, et al. A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol Cell 2000;5:207-16
   PubMed Web of Science ®Google Scholar
• Murtaugh LC, Stanger BZ, Kwan KM, Melton DA. Notch signaling controls multiple steps of pancreatic differentiation. Proc Natl Acad Sci USA 2003;100:14920-5
   PubMed Web of Science ®Google Scholar
• Esni F, Ghosh B, Biankin AV, et al. Notch inhibits Ptf1 function and acinar cell differentiation in developing mouse and zebrafish pancreas. Development 2004;131:4213-24
   PubMed Web of Science ®Google Scholar
• Miyamoto Y, Maitra A, Ghosh B, et al. Notch mediates TGFα-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 2003;3:565-76
   PubMed Web of Science ®Google Scholar
• Heiser PW, Hebrok M. Development and cancer: lessons learned in the pancreas. Cell Cycle 2004;3:270-2
   PubMed Web of Science ®Google Scholar
• van Es JH, van Gijn ME, Riccio O, et al. Notch/γ-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005;435:959-63
   PubMedGoogle Scholar
• Dyczynska E, Sun D, Yi H, et al. Proteolytic processing of delta-like 1 by ADAM proteases. J Biol Chem 2007;282:436-44
   PubMed Web of Science ®Google Scholar
• LaVoie MJ, Selkoe DJ. The Notch ligands, Jagged and Delta, are sequentially processed by α-secretase and presenilin/γ-secretase and release signaling fragments. J Biol Chem 2003;278:34427-37
   PubMed Web of Science ®Google Scholar
• Yamada D, Ohuchida K, Mizumoto K, et al. Increased expression of ADAM 9 and ADAM 15 mRNA in pancreatic cancer. Anticancer Res 2007;27:793-9
   PubMed Web of Science ®Google Scholar
• Grutzmann R, Luttges J, Sipos B, et al. ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br J Cancer 2004;90:1053-8
   PubMed Web of Science ®Google Scholar
• Yu Q, Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 1999;13:35-48
   PubMed Web of Science ®Google Scholar
• Yu WH, Woessner JF Jr, McNeish JD, Stamenkovic I. CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev 2002;16:307-23
   PubMed Web of Science ®Google Scholar
• Crawford HC, Matrisian LM. Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression. Invasion Metastasis 1994;14:234-45
   PubMedGoogle Scholar
• Bramhall SR, Stamp GW, Dunn J, et al. Expression of collagenase (MMP2), stromelysin (MMP3) and tissue inhibitor of the metalloproteinases (TIMP1) in pancreatic and ampullary disease. Br J Cancer 1996;73:972-8
   PubMed Web of Science ®Google Scholar
• Juuti A, Lundin J, Nordling S, et al. Epithelial MMP-2 expression correlates with worse prognosis in pancreatic cancer. Oncology 2006;71:61-8
   PubMed Web of Science ®Google Scholar
• Pryczynicz A, Guzinska-Ustymowicz K, Dymicka-Piekarska V, et al. Expression of matrix metalloproteinase 9 in pancreatic ductal carcinoma is associated with tumor metastasis formation. Folia Histochem Cytobiol 2007;45:37-40
   PubMedGoogle Scholar
• Balaz P, Friess H, Kondo Y, et al. Human macrophage metalloelastase worsens the prognosis of pancreatic cancer. Ann Surg 2002;235:519-27
   PubMed Web of Science ®Google Scholar
• Ito Y, Higashiyama S, Takeda T, et al. Expression of heparin-binding epidermal growth factor-like growth factor in pancreatic adenocarcinoma. Int J Gastrointest Cancer 2001;29:47-52
   PubMedGoogle Scholar
• Jones LE, Humphreys MJ, Campbell F, et al. Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival. Clin Cancer Res 2004;10:2832-45
   PubMed Web of Science ®Google Scholar
• Kuhlmann KF, van Till JW, Boermeester MA, et al. Evaluation of matrix metalloproteinase 7 in plasma and pancreatic juice as a biomarker for pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2007;16:886-91
   PubMed Web of Science ®Google Scholar
• Crawford HC, Scoggins CR, Washington MK, et al. Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas. J Clin Invest 2002;109:1437-44
   PubMed Web of Science ®Google Scholar
• McCaig C, Duval C, Hemers E, et al. The role of matrix metalloproteinase-7 in redefining the gastric microenvironment in response to Helicobacter pylori. Gastroenterology 2006;130:1754-63
   PubMedGoogle Scholar
• Hemers E, Duval C, McCaig C, et al. Insulin-like growth factor binding protein-5 is a target of matrix metalloproteinase-7: implications for epithelial-mesenchymal signaling. Cancer Res 2005;65:7363-9
   PubMed Web of Science ®Google Scholar
• Hashimoto G, Inoki I, Fujii Y, et al. Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165. J Biol Chem 2002;277:36288-95
   PubMed Web of Science ®Google Scholar
• Li Q, Park PW, Wilson CL, Parks WC. Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 2002;111:635-46
   PubMed Web of Science ®Google Scholar
• Conejo JR, Kleeff J, Koliopanos A, et al. Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int J Cancer 2000;88:12-20
   PubMedGoogle Scholar
• Hayashi T, Ishida Y, Kimura A, et al. IFN-γ protects cerulein-induced acute pancreatitis by repressing NF-κB activation. J Immunol 2007;178:7385-94
   PubMed Web of Science ®Google Scholar
• Ding K, Lopez-Burks M, Sanchez-Duran JA, et al. Growth factor-induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells. J Cell Biol 2005;171:729-38
   PubMedGoogle Scholar
• Sawey ET, Johnson, JA, Crawford HC. Matrix metalloproteinase type 7 controls pancreatic acinar cell transdifferentiation by activating the Notch signaling pathway. Proc Natl Acad Sci USA 2007;49:19327-32
   Google Scholar
• Guerra C, Schuhmacher AJ, Canamero M, et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 2007;11:291-302
   PubMed Web of Science ®Google Scholar
• Garg P, Ravi A, Patel NR, et al. Matrix metalloproteinase-9 regulates MUC-2 expression through its effect on goblet cell differentiation. Gastroenterology 2007;132:1877-89
   PubMed Web of Science ®Google Scholar
• Sternlicht MD, Lochter A, Sympson CJ, et al. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 1999;98:137-46
   PubMed Web of Science ®Google Scholar
• Iwano M, Plieth D, Danoff TM, et al. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002;110:341-50
   PubMed Web of Science ®Google Scholar
• Itoh Y, Seiki M. MT1-MMP: a potent modifier of pericellular microenvironment. J Cell Physiol 2006;206:1-8
   PubMed Web of Science ®Google Scholar
• Seiki M. Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett 2003;194:1-11
   PubMed Web of Science ®Google Scholar
• Sato H, Takino T, Okada Y, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994;370:61-5
   PubMed Web of Science ®Google Scholar
• Knäuper V, Will H, López-Otin C, et al. Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme. J Biol Chem 1996;271:17124-31
   PubMed Web of Science ®Google Scholar
• Hotary KB, Allen ED, Brooks PC, et al. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 2003;114:33-45
   PubMed Web of Science ®Google Scholar
• Koshikawa N, Minegishi T, Sharabi A, et al. Membrane-type matrix metalloproteinase-1 (MT1-MMP) is a processing enzyme for human laminin gamma 2 chain. J Biol Chem 2005;280:88-93
   PubMedGoogle Scholar
• Ellenrieder V, Alber B, Lacher U, et al. Role of MT-MMPs and MMP-2 in pancreatic cancer progression. Int J Cancer 2000;85:14-20
   PubMed Web of Science ®Google Scholar
• Kajita M, Itoh Y, Chiba T, et al. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol 2001;153:893-904
   PubMed Web of Science ®Google Scholar
• Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-44
   PubMed Web of Science ®Google Scholar
• Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev 2000;14:163-76
   PubMed Web of Science ®Google Scholar
• Huang SS, Huang JS. TGF-β control of cell proliferation. J Cell Biochem 2005;96:447-62
   PubMed Web of Science ®Google Scholar
• Zavadil J, Bottinger EP. TGF-β and epithelial-to-mesenchymal transitions. Oncogene 2005;24:5764-74
   PubMed Web of Science ®Google Scholar
• Yoo BM, Yeo M, Oh TY, et al. Amelioration of pancreatic fibrosis in mice with defective TGF-β signaling. Pancreas 2005;30:e71-9
   PubMedGoogle Scholar
• Patterson BC, Sang QA. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem 1997;272:28823-5
   PubMed Web of Science ®Google Scholar
• Ide T, Kitajima Y, Miyoshi A, et al. Tumor-stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c-Met pathway. Int J Cancer 2006;119:2750-9
   PubMed Web of Science ®Google Scholar
• Keim V, Witt H, Bauer N, et al. The course of genetically determined chronic pancreatitis. JOP 2003;4:146-54
   PubMedGoogle Scholar
• Lindstad RI, Sylte I, Mikalsen SO, et al. Pancreatic trypsin activates human promatrix metalloproteinase-2. J Mol Biol 2005;350:682-98
   PubMed Web of Science ®Google Scholar
• Mort JS, Recklies AD, Poole AR. Release of cathepsin B precursors from human and murine tumours. Prog Clin Biol Res 1985;180:243-5
   PubMedGoogle Scholar
• Johnson SK, Ramani VC, Hennings L, Haun RS. Kallikrein 7 enhances pancreatic cancer cell invasion by shedding E-cadherin. Cancer 2007;109:1811-20
   PubMed Web of Science ®Google Scholar
• Paciucci R, Tora M, Diaz VM, Real FX. The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro. Oncogene 1998;16:625-33
   PubMedGoogle Scholar
• Friess H, Cantero D, Graber H, et al. Enhanced urokinase plasminogen activation in chronic pancreatitis suggests a role in its pathogenesis. Gastroenterology 1997;113:904-13
   PubMedGoogle Scholar
• Aguilar S, Corominas JM, Malats N, et al. Tissue plasminogen activator in murine exocrine pancreas cancer: selective expression in ductal tumors and contribution to cancer progression. Am J Pathol 2004;165:1129-39
   PubMedGoogle Scholar
• Crippa MP. Urokinase-type plasminogen activator. Int J Biochem Cell Biol 2007;39:690-4
   PubMed Web of Science ®Google Scholar
• Monea S, Lehti K, Keski-Oja J, Mignatti P. Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism. J Cell Physiol 2002;192:160-70
   PubMed Web of Science ®Google Scholar
• Saunders WB, Bayless KJ, Davis GE. MMP-1 activation by serine proteases and MMP-10 induces human capillary tubular network collapse and regression in 3D collagen matrices. J Cell Sci 2005;118:2325-40
   PubMed Web of Science ®Google Scholar
• Hurtado M, Lozano JJ, Castellanos E, et al. Activation of the epidermal growth factor signalling pathway by tissue plasminogen activator in pancreas cancer cells. Gut 2007;56:1266-74
   PubMedGoogle Scholar
• Choong PF, Nadesapillai AP. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. Clin Orthop Relat Res 2003:S46-58
   Google Scholar
• Roldan AL, Cubellis MV, Masucci MT, et al. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 1990;9:467-74
   PubMed Web of Science ®Google Scholar
• Hajjar KA, Jacovina AT, Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J Biol Chem 1994;269:21191-7
   PubMed Web of Science ®Google Scholar
• Vishwanatha JK, Chiang Y, Kumble KD, et al. Enhanced expression of annexin II in human pancreatic carcinoma cells and primary pancreatic cancers. Carcinogenesis 1993;14:2575-9
   PubMedGoogle Scholar
• Ortiz-Zapater E, Peiro S, Roda O, et al. Tissue plasminogen activator induces pancreatic cancer cell proliferation by a non-catalytic mechanism that requires extracellular signal-regulated kinase 1/2 activation through epidermal growth factor receptor and annexin A2. Am J Pathol 2007;170:1573-84
   PubMedGoogle Scholar
• Ragno P, Estreicher A, Gos A, et al. Polarized secretion of urokinase-type plasminogen activator by epithelial cells. Exp Cell Res 1992;203:236-43
   PubMedGoogle Scholar
• Ellenrieder V, Hendler SF, Ruhland C, et al. TGF-beta-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system. Int J Cancer 2001;93:204-11
   PubMed Web of Science ®Google Scholar
• Bauer TW, Liu W, Fan F, et al. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. Cancer Res 2005;65:7775-81
   PubMed Web of Science ®Google Scholar
• Sawai H, Okada Y, Funahashi H, et al. Interleukin-1α enhances the aggressive behavior of pancreatic cancer cells by regulating the α6β1-integrin and urokinase plasminogen activator receptor expression. BMC Cell Biol 2006;7:8. Published online 20 February 2006, doi:10.1186/1471-2121-7-8
   PubMedGoogle Scholar
• Lerch MM, Halangk W, Kruger B. The role of cysteine proteases in intracellular pancreatic serine protease activation. Adv Exp Med Biol 2000;477:403-11
   PubMedGoogle Scholar
• Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985;315:115-22
   PubMed Web of Science ®Google Scholar
• Gocheva V, Zeng W, Ke D, et al. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev 2006;20:543-56
   PubMed Web of Science ®Google Scholar
• Joyce JA, Hanahan D. Multiple roles for cysteine cathepsins in cancer. Cell Cycle 2004;3:1516-619
   PubMed Web of Science ®Google Scholar
• Guo M, Mathieu PA, Linebaugh B, et al. Phorbol ester activation of a proteolytic cascade capable of activating latent transforming growth factor-β a process initiated by the exocytosis of cathepsin B. J Biol Chem 2002;277:14829-37
   PubMedGoogle Scholar
• Kostoulas G, Lang A, Nagase H, Baici A. Stimulation of angiogenesis through cathepsin B inactivation of the tissue inhibitors of matrix metalloproteinases. FEBS Lett 1999;455:286-90
   PubMed Web of Science ®Google Scholar
• Felbor U, Dreier L, Bryant RA, et al. Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J 2000;19:1187-94
   PubMed Web of Science ®Google Scholar
• Szpaderska AM, Frankfater A. An intracellular form of cathepsin B contributes to invasiveness in cancer. Cancer Res 2001;61:3493-500
   PubMedGoogle Scholar
• Zwad O, Kubler B, Roth W, et al. Decreased intracellular degradation of insulin-like growth factor binding protein-3 in cathepsin L-deficient fibroblasts. FEBS Lett 2002;510:211-5
   PubMedGoogle Scholar
• Wang B, Sun J, Kitamoto S, et al. Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J Biol Chem 2006;281:6020-9
   PubMed Web of Science ®Google Scholar
• Niedergethmann M, Hildenbrand R, Wolf G, et al. Angiogenesis and cathepsin expression are prognostic factors in pancreatic adenocarcinoma after curative resection. Int J Pancreatol 2000;28:31-9
   PubMedGoogle Scholar
• Niedergethmann M, Wostbrock B, Sturm JW, et al. Prognostic impact of cysteine proteases cathepsin B and cathepsin L in pancreatic adenocarcinoma. Pancreas 2004;29:204-11
   PubMed Web of Science ®Google Scholar
• Chung SM, Kawai K. Variant cathepsin B activity secreted from human pancreatic cancer cell lines into protein-free chemically defined medium. Gastroenterol Jpn 1989;24:699-706
   PubMedGoogle Scholar
• Azuma T, Hirai M, Ito S, et al. Expression of cathepsin E in pancreas: a possible tumor marker for pancreas, a preliminary report. Int J Cancer 1996;67:492-7
   PubMedGoogle Scholar
• Uno K, Azuma T, Nakajima M, et al. Clinical significance of cathepsin E in pancreatic juice in the diagnosis of pancreatic ductal adenocarcinoma. J Gastroenterol Hepatol 2000;15:1333-8
   PubMed Web of Science ®Google Scholar
• Bramhall SR, Rosemurgy A, Brown PD, et al. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001;19:3447-55
   PubMed Web of Science ®Google Scholar
• Bramhall SR, Hallissey MT, Whiting J, et al. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer 2002;86:1864-70
   PubMed Web of Science ®Google Scholar
• Fingleton B. Matrix metalloproteinases as valid clinical targets. Curr Pharm Des 2007;13:333-46
   PubMed Web of Science ®Google Scholar
• Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295:2387-92
   PubMed Web of Science ®Google Scholar
• McCawley LJ, Crawford HC, King LE Jr, et al. A protective role for matrix metalloproteinase-3 in squamous cell carcinoma. Cancer Res 2004;64:6965-72
   PubMed Web of Science ®Google Scholar
• McIntyre JO, Fingleton B, Wells KS, et al. Development of a novel fluorogenic proteolytic beacon for in vivo detection and imaging of tumour-associated matrix metalloproteinase-7 activity. Biochem J 2004;377:617-28
   PubMedGoogle Scholar
• Bremer C, Tung CH, Weissleder R. Molecular imaging of MMP expression and therapeutic MMP inhibition. Acad Radiol 2002;9(Suppl 2):S314-5
   Google Scholar
• Bergers G, Javaherian K, Lo KM, et al. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999;284:808-12
   PubMed Web of Science ®Google Scholar
• Joyce JA, Baruch A, Chehade K, et al. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 2004;5:443-53
   PubMed Web of Science ®Google Scholar
• Keller UA, Doucet A, Overall CM. Protease research in the era of systems biology. Biol Chem 2007;388:1159-62
   PubMedGoogle Scholar
• Koshiba T, Hosotani R, Wada M, et al. Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma. Cancer 1998;82:642-50
   PubMed Web of Science ®Google Scholar
• Haro H, Crawford HC, Fingleton B, et al. Matrix metalloproteinase-7-dependent release of tumor necrosis factor-α in a model of herniated disc resorption. J Clin Invest 2000;105:143-50
   PubMed Web of Science ®Google Scholar
• Nagakawa Y, Aoki T, Kasuya K, et al. Histologic features of venous invasion, expression of vascular endothelial growth factor and matrix metalloproteinase-2 and matrix metalloproteinase-9, and the relation with liver metastasis in pancreatic cancer. Pancreas 2002;24:169-78
   PubMed Web of Science ®Google Scholar
• Gress TM, Muller-Pillasch F, Lerch MM, et al. Expression and in situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer 1995;62:407-13
   PubMed Web of Science ®Google Scholar
• Cantero D, Friess H, Deflorin J, et al. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer 1997;75:388-95
   PubMed Web of Science ®Google Scholar